tetano
Editor, Senior Moderator
Int J Biol Macromol
. 2023 Dec 30:129126.
doi: 10.1016/j.ijbiomac.2023.129126. Online ahead of print. Engineering of novel hemagglutinin biosensors for rapid detection and drug screening of Influenza A H7N9 virus
Xin Chen[SUP] 1 [/SUP], Yuan Huang[SUP] 1 [/SUP], Peixuan Gao[SUP] 1 [/SUP], Fang Wu[SUP] 1 [/SUP], Yongyue Han[SUP] 1 [/SUP], Chuwen Zhang[SUP] 1 [/SUP], Zhuowen Hu[SUP] 2 [/SUP], Fang Zhao[SUP] 3 [/SUP], Dmitry N Shcherbakov[SUP] 4 [/SUP], Weiqi Pan[SUP] 5 [/SUP], Xuefeng Niu[SUP] 5 [/SUP], Xiaoyan Li[SUP] 6 [/SUP], Shuwen Liu[SUP] 7 [/SUP], Wei Xu[SUP] 8 [/SUP]
Affiliations
New pathogenic influenza virus strains are constantly emerging, posing a serious risk to both human health and economic growth. To effectively control the spread of this virus, there is an urgent need for early, rapid, sensitive, simple, and cost-effective detection technologies, as well as new and effective antiviral drugs. In this study, we have successfully achieved a significant milestone by successfully fusing the H7N9 influenza virus hemagglutinin (HA) protein with the nano-luciferase component, resulting in the development of a novel set of biosensors. This remarkable achievement marks the first instance of utilizing this biosensor technology for influenza antibody detection. Our biosensor technology also has the potential to facilitate the development of antiviral drugs targeting specific epitopes of the HA protein, providing a promising avenue for the treatment of H7N9 influenza virus infections. Furthermore, our biosensors have broad applications beyond H7N9 influenza virus detection, as they can be expanded for the detection of other pathogens and drug screening applications in the future. By providing a novel and effective solution to the detection and treatment of influenza viruses, our biosensors have the potential to revolutionize the field of infectious disease control.
Keywords: Antibody; Antiviral drugs; Biosensor; H7N9 influenza; Hemagglutinin.
. 2023 Dec 30:129126.
doi: 10.1016/j.ijbiomac.2023.129126. Online ahead of print. Engineering of novel hemagglutinin biosensors for rapid detection and drug screening of Influenza A H7N9 virus
Xin Chen[SUP] 1 [/SUP], Yuan Huang[SUP] 1 [/SUP], Peixuan Gao[SUP] 1 [/SUP], Fang Wu[SUP] 1 [/SUP], Yongyue Han[SUP] 1 [/SUP], Chuwen Zhang[SUP] 1 [/SUP], Zhuowen Hu[SUP] 2 [/SUP], Fang Zhao[SUP] 3 [/SUP], Dmitry N Shcherbakov[SUP] 4 [/SUP], Weiqi Pan[SUP] 5 [/SUP], Xuefeng Niu[SUP] 5 [/SUP], Xiaoyan Li[SUP] 6 [/SUP], Shuwen Liu[SUP] 7 [/SUP], Wei Xu[SUP] 8 [/SUP]
Affiliations
- PMID: 38163504
- DOI: 10.1016/j.ijbiomac.2023.129126
New pathogenic influenza virus strains are constantly emerging, posing a serious risk to both human health and economic growth. To effectively control the spread of this virus, there is an urgent need for early, rapid, sensitive, simple, and cost-effective detection technologies, as well as new and effective antiviral drugs. In this study, we have successfully achieved a significant milestone by successfully fusing the H7N9 influenza virus hemagglutinin (HA) protein with the nano-luciferase component, resulting in the development of a novel set of biosensors. This remarkable achievement marks the first instance of utilizing this biosensor technology for influenza antibody detection. Our biosensor technology also has the potential to facilitate the development of antiviral drugs targeting specific epitopes of the HA protein, providing a promising avenue for the treatment of H7N9 influenza virus infections. Furthermore, our biosensors have broad applications beyond H7N9 influenza virus detection, as they can be expanded for the detection of other pathogens and drug screening applications in the future. By providing a novel and effective solution to the detection and treatment of influenza viruses, our biosensors have the potential to revolutionize the field of infectious disease control.
Keywords: Antibody; Antiviral drugs; Biosensor; H7N9 influenza; Hemagglutinin.